In an annoucement today from Pfizer, the Government of Canada has entered into an agreement with the Pfizer and BioNTech to supply the partnership's BNT162 mRNA-based vaccine to combat COVID-19.
Simply put: If a vaccine is available, who will take it? Pfizer alone estimates 100 million doses of their vaccine will be available. That figure is roughly between 1/4 to 1/3 the population of the United States. In recent polls, only 25% of Americans...
According to the Russian health minister Mikhail Murashko, the program will first vaccinate doctors and teachers provided their first vaccine receives regulatory approval this month.
Pending final contract, healthcare and pharmaceutical companies GSK and Sanofi announced an agreement with the UK government to supply 60 million doses of the partnership's COVID-19 vaccine, currently under development.
We update our COVID-19 vaccine progress every day on our progress page. Here's our weekly report.
Today Pfizer and BioNTech have jointly announced they are prepared to begin their Phase II/III global trials for their COVID-19 vaccine partnership. Following on review of Phase I/II trial results, the partnership worked with the FDA to select BNT162b2 as the vaccine candidate in the next phases.
The agreement will expand funding by up to $472 million in part to support the Phase 3 study of mRNA-1273, the company's COVID-19 vaccine. This funding expands on Moderna's previous agreement with BARDA for $483 million.
Pfizer and BioNTech biopharmaceutics announced today a $1.95 billion dollar agreement with the U.S. government for 100 million doses of the partnership's BNT162 program vaccine.